Effect of timolol on late ventricular arrhythmias after acute myocardial infarction.
This is a subproject of the Norwegian timolol myocardial infarction study carried out at one of the clinical centers. High risk patients surviving either a reinfarction or large initial infarction were randomized to placebo (44 pts) or timolol (37 pts). A 24 hour ECG was obtained the day before randomization (at baseline, 7-28 days after the acute attack) then 3 days, 1 month and 6 months after start of therapy. During this period the number of patients with one or more of ventricular couplets, bigemini, ventricular tachycardia or early cycle premature ventricular contractions (PVC) (i.e. complex ventricular arrhythmias) and the average number of PVC per hour increased significantly in the placebo group but not in the timolol group. The results indicate that there is an increased severity and incidence of ventricular arrhythmias in the first 6 months after myocardial infarction. Timolol effectively inhibited this trend. The importance of timolol as an antiarrhythmic agent may therefore be to prevent subclinical infarction extension and secondary ventricular arrhythmias related to the size of the myocardial damage.
D001145:Arrhythmias, Cardiac / Q000150:complications / Q000517:prevention & control*; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011412:Propanolamines / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use*
D011412:Propanolamines; D013999:Timolol